News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics’ 2023 Annual Report published

April 15, 2024

Stockholm, Sweden, April 15, 2024 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) Annual Report for 2023 is available (in Swedish) attached to this press release and at the Company’s website, An English translation of the Annual Report will be published shortly.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10